Sou Hu Cai Jing·2026-01-30 12:05Core Viewpoint - Rongchang Biologics (09995.HK) anticipates significant revenue growth and profitability turnaround in 2025, projecting a revenue increase of approximately RMB 1.533 billion, representing a year-on-year growth of about 89% [1] Financial Projections - The company expects to achieve an operating revenue of approximately RMB 3.25 billion in 2025, compared to the previous year [1] - Net profit attributable to the parent company is projected to be around RMB 716 million, indicating a return to profitability [1] - The net profit after deducting non-recurring gains and losses is estimated at approximately RMB 78.5 million, also reflecting a turnaround from losses [1] Stock Performance - As of January 30, 2026, Rongchang Biologics closed at HKD 84.2, down 0.41%, with a trading volume of 2.8142 million shares and a turnover of HKD 238 million [1] - The stock has received a majority "buy" rating from investment banks, with four firms issuing "buy" ratings in the last 90 days [1] - The average target price over the last 90 days is HKD 108.33, with a recent report from Zhongtai International giving a target price of HKD 114 [1] Market Position - Rongchang Biologics has a market capitalization of HKD 17.636 billion, ranking 8th in the biopharmaceutical sector [1]